The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters

Uterine fibroids and endometriosis are two frequent diseases among women of reproductive age. They can be responsible for chronic and/or menstrual pelvic pain and abnormal uterine bleeding. The first-line management of these conditions relies on medical treatment. Hormonal treatment with contraceptive pill can be effective, although up to 30% of patients do not respond to this line of treatment. In this context, GnRH antagonists have been introduced. By suppressing ovulation, they inhibit the action of the gonadal axis and thus can reduce bleeding and pain associated with uterine fibroids and

Trial Details

NCT ID
NCT07173127
Phase
NA
Sponsor
University Hospital, Geneva
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Ryeqo treatment
Locations (sample)
  • Geneva, Canton of Geneva, Switzerland|46.20222,6.14569

Key Eligibility Criteria

  • Women consulting at the DFEA of the HUG, who are prescribed Ryeqo® for a qualified medical condition
  • Age ≥ 18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →